First-of-its-kind vaccine expands malaria protection for pregnant women

Sanaria® PfSPZ Vaccine protects women against malaria before and during pregnancy for at least two years

20-Aug-2024 - In a report a team led by investigators at the Malaria Research and Training Center (MRTC), Bamako, Mali; the Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases, National Institutes of Health; and Sanaria Inc. describes the durable ...

Investigational monoclonal antibody to treat Ebola is safe in adults

28-Jan-2019 - The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial. Eighteen healthy adults received the monoclonal antibody as part of a Phase 1 clinical trial that began in May 2018 at the National Institutes of ...

Research offers clues for improved influenza vaccine design

10-Apr-2018 - Influenza vaccines that better target the influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and lessen the severity of illness, according to new researchl. Current seasonal influenza vaccines mainly target a different, more ...

Monoclonal Antibodies Against Zika Show Promise in Monkey Study

09-Oct-2017 - Using blood samples from an individual previously infected with Zika virus, scientists funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have developed an antibody-based Zika virus therapeutic that protected monkeys from ...

Mycobacteria use protein to create diverse populations, avoid drugs

02-Jun-2017 - Subgroups of tuberculosis (TB)-causing bacteria can persist even when antibiotics wipe out most of the overall population. The need to eliminate these persistent subpopulations is one reason why TB treatment regimens are so lengthy. Now, researchers have shown that a single protein allows ...

Sanaria Inc. and the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant

18-Jun-2012 - Sanaria Inc and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the ...

NIH renews research program to develop medical countermeasures against radiological, nuclear threats

23-Aug-2010 - A major research effort to develop medical products to diagnose, prevent and treat the short- and long-term consequences of radiation exposure after a radiological or nuclear terrorist attack has been renewed by the National Institute of Allergy and Infectious Diseases (NIAID), part of the ...

Virus-like particle vaccine protects monkeys from chikungunya virus

02-Feb-2010 - An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of ...

Blood stem-cell transplant regimen reverses sickle cell disease in adults

15-Dec-2009 - A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the New England Journal of Medicine. The trial was conducted at the ...

HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study

28-Sep-2009 - In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. Following a final analysis of the trial data, the Surgeon ...